Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Non-Current Assets (2020 - 2025)

SOPHiA GENETICS's Non-Current Assets history spans 6 years, with the latest figure at $64.0 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 14.4% to $64.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $64.0 million, a 14.4% increase, with the full-year FY2025 number at $64.0 million, up 14.4% from a year prior.
  • Non-Current Assets hit $64.0 million in Q4 2025 for SOPHiA GENETICS, up from $60.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for SOPH hit a ceiling of $64.0 million in Q4 2025 and a floor of $23.8 million in Q2 2021.
  • Historically, Non-Current Assets has averaged $49.9 million across 5 years, with a median of $54.6 million in 2023.
  • Biggest five-year swings in Non-Current Assets: soared 79.13% in 2022 and later dropped 3.79% in 2024.
  • Tracing SOPH's Non-Current Assets over 5 years: stood at $37.3 million in 2021, then grew by 27.51% to $47.6 million in 2022, then increased by 22.12% to $58.1 million in 2023, then fell by 3.79% to $55.9 million in 2024, then rose by 14.4% to $64.0 million in 2025.
  • Business Quant data shows Non-Current Assets for SOPH at $64.0 million in Q4 2025, $60.0 million in Q3 2025, and $60.6 million in Q2 2025.